Dr. Markus Kostrzewa will elaborate on the progress that has been made in Bruker Microbiology & Diagnostics, specifically on the innovation and evolution of the FDA-cleared MALDI Biotyper® CA System. The discussion will begin by presenting the evolution of the MALDI-TOF mass spectrometer and the key innovative changes since FDA clearance in 2013. Dr. Kostrzewa will then discuss the latest expansion of the MALDI Biotyper CA System Reference Library followed by details in the development of the FDA-cleared MBT Sepsityper® Kit US IVD which provides a microbial ID direct from positive blood culture in less than 20 minutes for over 488 organisms. To conclude the presentation, Dr. Kostrzewa will briefly present Bruker's ongoing innovation projects and studies to further enhance technologies to address today’s critical diseases.

Learning Objectives

• Explain the advantages of MALDI-TOF technology over traditional microbiology techniques for microbial identification

• Discuss how rapid microbial ID testing direct from positive blood cultures can impact patient outcomes

• Discuss how the implementation of rapid microbial ID testing direct from positive blood cultures can positively impact the clinical institution